Proactive therapeutic drug monitoring of adalimumab for pediatric Crohn's disease patients: A cost-effectiveness analysis.

Published in: Journal of gastroenterology and hepatology (2021)

Proactive TDM for ADL seems to gain higher QALYs at lower cost in pediatric CD patients.

Keyphrases